Influenza H5 Hemagglutinin DNA Primes the Antibody Response Elicited by the Live Attenuated Influenza A/Vietnam/1203/2004 Vaccine in Ferrets

Amorsolo L. Suguitan Jr.1, Xing Cheng1, Weijia Wang1, Shixia Wang2, Hong Jin1*, Shan Lu2

1 MedImmune, Mountain View, California, United States of America, 2 Department of Medicine, University of Massachusetts Medical School, Worcester, Massachusetts, United States of America

Abstract

Priming immunization plays a key role in protecting individuals or populations to influenza viruses that are novel to humans. To identify the most promising vaccine priming strategy, we have evaluated different prime-boost regimens using inactivated, DNA and live attenuated vaccines in ferrets. Live attenuated influenza A/Vietnam/1203/2004 (H5N1) candidate vaccine (LAIV, VN04 ca) primed ferrets efficiently while inactivated H5N1 vaccine could not prime the immune response in seronegative ferrets unless an adjuvant was used. However, the H5 HA DNA vaccine alone was as successful as an adjuvanted inactivated VN04 vaccine in priming the immune response to VN04 ca virus. The serum antibody titers of ferrets primed with H5 HA DNA followed by intranasal vaccination of VN04 ca virus were comparable to that induced by two doses of VN04 ca virus. Both LAIV-LAIV and DNA-LAIV vaccine regimens could induce antibody responses that cross-neutralized antigenically distinct H5N1 virus isolates including A/HongKong/213/2003 (HK03) and prevented nasal infection of HK03 vaccine virus. Thus, H5 HA DNA vaccination may offer an alternative option for pandemic preparedness.

Citation: Suguitan AL Jr, Cheng X, Wang W, Wang S, Jin H, et al. (2011) Influenza H5 Hemagglutinin DNA Primes the Antibody Response Elicited by the Live Attenuated Influenza A/Vietnam/1203/2004 Vaccine in Ferrets. PLoS ONE 6(7): e21942. doi:10.1371/journal.pone.0021942

Editor: Stephen Mark Tompkins, University of Georgia, United States of America

Received April 27, 2011; Accepted June 13, 2011; Published July 8, 2011

Copyright: © 2011 Suguitan Jr et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This work was supported in part by NIH/NIAID grant AI078073. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. No additional external funding received for this study.

Competing Interests: The authors are employees of MedImmune company. This does not alter the authors’ adherence to all the PLoS ONE policies on sharing data and materials.

* E-mail: jinh@medimmune.com

Introduction

Influenza pandemics of varying severities have occurred in the last century. The 1918 “Spanish flu” (H1N1) that claimed the lives of about 40 million people is perhaps one of the deadliest pandemics in history [1]. The 1957 “Asian flu” (H2N2) and the 1968 “Hong Kong flu” (H3N2) pandemics are believed to have been caused by viruses from reassortment of circulating human strains and avian viruses [2]. The recent emergence of the swine-origin influenza A/H1N1 pandemic (pH1N1) virus is a sober reminder that viruses with novel antigenic properties can infect and spread among an immunologically naive human population with potentially devastating consequences.

Among the avian influenza viruses that have sporadically infected humans, highly pathogenic avian influenza (HPAI) H5N1 viruses pose the greatest threat due to their high virulence. As of February 2011, there have been 525 laboratory-confirmed cases of H5N1 infection, resulting in 310 deaths (~59% mortality) [3]. There are concerns that H5N1 viruses could evolve and adapt to replicate and spread in the human population or gain human-to-human transmissibility through reassortment with circulating human influenza A viruses [4]. The 2009 pH1N1 virus has a high genetic compatibility with an avian H5N1 virus, raising the possibility that HPAI H5N1 viruses could acquire the ability of being readily transmitted among individuals [5]. Thus, the development of safe and efficacious vaccines against these viruses is a public health priority.

Vaccination is an integral component of strategies aiming to prevent and control pandemic influenza. Designed to mimic the route of natural infection, live attenuated influenza virus (LAIV) vaccines induce both local mucosal and systemic immunity [6] and are able to elicit broad immune responses against antigenically drifted strains [7,8,9,10]. An H5N1 LAIV vaccine was generated by reverse genetics by combining the surface glycoprotein gene segments of A/Vietnam/1203/2004 (H5N1, VN04) and the six internal protein gene segments of the cold-adapted A/Ann Arbor/6/60 (H2N2, AA ca) master donor vaccine strain that confer the cold-adapted (ca), temperature-sensitive (ts), and attenuation (att) phenotypes to the reassortant vaccine virus [11,12]. Our previous pre-clinical studies showed that a single dose of VN04 ca elicited low levels of neutralizing antibodies in mice and ferrets four weeks after immunization. Although a single dose of VN04 ca completely protected animals from challenge infection of lethal doses of homologous and heterologous H5N1 wild-type (wt) viruses, two doses of VN04 ca were required for complete protection from pulmonary virus replication [12].

To prevent or control influenza pandemics caused by HPAI H5N1 strains, multiple vaccinations or different vaccine prime boost approaches might be needed. DNA vaccination with plasmids expressing influenza viral proteins from the highly variable hemagglutinin (HA) to the more conserved matrix and nucleoprotein have been shown to induce humoral and cell-mediated immune responses in various animal species [13,14,15]. Although DNA vaccination can induce antibody responses...
comparable to unadjuvanted protein antigens [16], DNA vaccine alone is not as efficient as an adjuvanted protein vaccine. However, DNA vaccines could serve as a priming agent to significantly increase the immunogenicity of a protein vaccine. Such DNA prime-protein boost approach has been successfully exploited to improve the breadth of the cellular and humoral immune response elicited by various vaccines against different bacterial and protozoan pathogens in animal studies [17,18,19,20,21], as well as in an HIV vaccine study in humans [22]. Wei et al. (2010) recently reported that H1 HA DNA priming followed by a TIV boost not only led to increased neutralizing antibody titers but also broadened the response to antigenically distant H1N1 virus strains [23]. Huber et al. (2009) showed that boosting H3 HA DNA-primed mice with H3N2 and PR8 reassortant viruses induced a robust and broad antibody response against multiple H3N2 virus strains [24].

Since LAIV vaccination encourages development of a durable mucosal immune response and robust cell-mediated immunity, we evaluated several heterologous prime-boost regimens that would augment the immunogenicity of live attenuated VN04 ca candidate vaccine in ferrets. Our results indicate that an H5 HA DNA vaccine successfully primed the immune response that was subsequently boosted by VN04 ca virus. The protective immune response induced by H5 HA DNA prime-VN04 ca virus boost is comparable to that elicited by two doses of VN04 ca virus; both regimens protected ferrets from an antigenically distinct H5N1 virus replication in the respiratory tract.

Results

Antibody response from LAIV and inactivated H5N1 protein vaccine regimen

An unadjuvanted inactivated VN04 (iVN04) monovalent subvirus influenza vaccine was previously shown to be less immunogenic in humans and requires a vaccine dose of 90 μg of HA antigen in multiple doses to induce an antibody response similar to that of seasonal influenza vaccine [25,26]. As vaccine supply will likely be limited during a pandemic, administering such large quantities of antigen in multiple doses would be unrealistic and inefficient. We therefore compared various prime-boost strategies in seronegative ferrets using iVN04 and VN04 ca virus to determine whether priming with either vaccine will be more immunogenic than immunization with a single form of the vaccine (Table 1). Ferrets primed with iVN04 did not have any detectable serum neutralizing antibody titers (Nt Ab) 28 days post-vaccination (Groups 2–4), but all ferrets primed with VN04 ca virus had detectable levels of serum Nt Ab after the first dose (Groups 5–7). The serum Nt Ab titers (51–62) elicited by a single dose of VN04 ca virus were slightly lower than what was reported previously [12]. The Nt Ab titers in ferrets that received only a single dose of VN04 ca virus declined from 51 to 20 at 8 weeks post-vaccination (Group 5). Vaccination of ferrets with iVN04 adjuvanted with TiterMax, a stable water-in-oil emulsion commonly used in animal studies, elicited serum Nt Ab response (titer of 48) after the first dose and further increased to a titer of 190 following a boost with VN04 ca virus (Group 8). Two doses of iVN04 failed to induce any serum Nt Ab response (Group 3) due to lack of live virus priming in seronegative hosts [27]. Boosting of animals primed with iVN04 (Group 4), VN04 ca virus (Group 6), or adjuvanted iVN04 (Group 8) induced higher serum Nt Ab titers than that elicited by a single dose. However, iVN04 is the least efficient in priming the antibody response (titer of 95 vs 160 or 190). The antibody response of VN04 ca virus-primed ferrets was boosted with iVN04 without adjuvant (Group 6). Due to the small sample size of animals used in this study (n = 4/group), statistically significant differences in the geometric mean antibody titers between different groups were not consistently achieved. Despite this caveat, our data indicated that VN04 ca virus or adjuvanted iVN04 virus can successfully prime seronegative hosts to mount a higher immune response following boost with VN04 ca virus or iVN04.

Expression of H5 HA protein from DNA

Since the use of a pandemic LAIV such as VN04 ca virus vaccine prior to a pandemic may be restricted and iVN04 requires adjuvant or a larger dose to prime the immune response against novel influenza viruses, the prime-boost regimen of H5 HA DNA and VN04 ca virus was thus considered for evaluation in ferrets. Our previous studies showed that the HA antigens were expressed more efficiently when the natural leader sequence was replaced with the tPA leader sequence [28]. Thus, the H5 VN tPA DNA containing tPA and codon-optimized HA cDNA including the ectodomain, transmembrane domain and cytoplasmic tail (Figure 1A) was used in the current study. The expression of H5 HA antigen from H5 DNA-transfected 293T cells was confirmed by Western blot (Figure 1B). The HA protein remained cell-associated; no protein was detected in the transfected cell culture supernatant. The H5 HA DNA vaccine contains multi-basic amino acid sequences at the cleavage site between the HA1 and HA2 (PQREXRRKKRRG). The expressed HA protein was cleaved to HA1 and HA2 in addition to the HA0 in the transfected cells.

Antibody response from H5 HA DNA prime and H5N1 LAIV boost regimen

Serum antibody responses were measured by ELISA, HA1 and neutralization assays. Recombinant H5 HA-specific IgG and IgA antibody titers were determined and presented in Figure 2. Very low levels of HA-specific IgG antibody were detected in ferrets that received the H5 HA DNA vaccine alone, even after the third dose (Figure 2A) when the needle injection was used to deliver the DNA vaccine. In contrast, ferrets that were primed with the H5 HA DNA and boosted with VN04 ca virus reached a slightly higher mean HA-specific IgG titer than ferrets that received two doses of VN04 ca virus or VN04 ca virus prime-H5 HA DNA boost

Table 1. Ferret serum antibody titers from vaccination with iVN04 and VN04 ca.

| Group | Vaccine dose | GMT Nt antibody against VN04 ca virus |
|-------|--------------|-----------------------------------|
|       | Prime | Boost | Post dose 1 | Post dose 2 |
| 1     | PBS   | PBS   | <10         | <10         |
| 2     | iVN04 | PBS   | <10         | <10         |
| 3     | iVN04 | iVN04 | <10         | <10         |
| 4     | VN04 ca | VN04 ca | <10 | 95 |
| 5     | VN04 ca | PBS   | 51         | 20          |
| 6     | VN04 ca | iVN04 | 62         | 160         |
| 7     | VN04 ca | VN04 ca | 62         | 123         |
| 8     | iVN04/TiterMax | VN04 ca | 48         | 190         |

Ferrets were inoculated with 10⁷ PFU of VN04 ca intranasally or 15 μg of VN04 vaccine intramuscularly. Blood was collected 4 weeks after each dose and the H5N1-specific antibody levels (expressed as geometric mean titers) were determined by microneutralization assay. doi:10.1371/journal.pone.0021942.t001
These three vaccine regimens also elicited comparable levels of HA-specific IgA serum titers while DNA vaccination alone induced very modest levels of HA-specific IgA antibody (Figure 2B). Interestingly, both the H5 HA-specific serum IgG and IgA titers elicited by the various vaccine regimens declined four weeks after the boost. This decrease in influenza-specific antibody titers has also been described previously for a seasonal H3N2 strain in mice [29]. In contrast to binding antibodies, the serum Nt Ab titers remained at comparable levels between two and four weeks after the boost (Figure 2C).

The levels of HA-specific antibodies in immunized ferret sera were also measured by microneutralization assay (left panel) and HAI assay (right panel, Figure 3). The breadth of the serum Nt and HAI Ab titers against antigenically distinct H5N1 influenza A/Hong Kong/213/2003 from clade 1 (HK03), A/Anhui/1/2005 from clade 2.3.4 (AH05), and A/Indonesia/5/2005 from clade 2.1 (IN05) ca strains was also examined. Ferrets that were primed with VN04 ca virus displayed low levels of serum Nt Ab titers against the homologous vaccine virus 4 weeks post-immunization (Groups 2 and 3, Figure 3A, left panel) while ferrets that were primed with the H5 HA DNA exhibited barely detectable serum Nt Ab at the same time point (Groups 4 and 5). Ferrets that received 2 doses of VN04 ca virus (Group 2) or those that received the prime-boost regimen (Groups 3 and 4) had higher serum Nt Ab titers. Three doses of the H5 HA DNA vaccine elicited a low level of serum Nt Ab titers (Group 5). A very similar pattern of results was also observed for serum HAI Ab against the VN04 ca virus (Figure 3A, right panel).

The prime-boost strategies (Groups 3 and 4, Figure 5) induced serum Nt and HAI Ab titers that cross reacted to the variant H5N1 viruses tested in this study at levels comparable to that elicited by two doses of VN04 ca virus (Group 2). In contrast, ferrets that were immunized with the H5 HA DNA vaccine alone exhibited barely detectable Ab titers against AH05 and IN05 and low serum Nt Ab titers to HK03 (Group 5, Figure 3C, 3D and 3B, respectively).
We then examined whether this cross-reactive antibody response to variant H5N1 viruses would confer protection in vivo (Figure 4). All immunized ferrets were challenged with the HK03 ca vaccine virus. Because of the attenuated phenotype of this challenge virus, viral replication could only be measured in the upper respiratory tract of ferrets. Ferrets that either received two doses of the VN04 ca virus or those that were primed with H5 HA DNA followed by VN04 ca virus boost were completely protected from HK03 ca virus replication in the nasal turbinates (Groups 2 and 4, \( p < 0.05 \)). The group that was primed with VN04 ca virus and boosted with H5 HA DNA also had significantly reduced viral titers in the upper respiratory tract (Group 3, \( p < 0.05 \)). The ferrets that received H5 HA DNA vaccine alone (Group 5) were not protected against HK03 ca virus replication; viral titer in the NT was similar to the vector control group (Group 1). Thus, similar to two doses of VN04 ca vaccination, H5 HA DNA prime-VN04 ca

**Figure 2.** Kinetics of the development of H5 HA-specific serum IgG (A), IgA (B), and neutralizing antibodies (C) elicited by various H5N1 prime-boost regimens. Ferrets were immunized with either 10^7 PFU of VN04 ca virus (weeks 0 and 4) or 200 \( \mu \)g of H5 HA DNA (weeks 0, 2 and/or 4) and serum samples were collected regularly at 2-week intervals. H5 HA-specific IgG and IgA in ferret serum samples (\( N = 4 \)/group) were determined by ELISA using recombinant VN04 H5 HA as antigen. Neutralizing antibody titers against 100 TCID\(_{50}\) of the VN04 ca virus are depicted. Geometric mean titers from each group are shown.

doi:10.1371/journal.pone.0021942.g002
Figure 3. Serum antibody titers against homologous and variant H5N1 \textit{ca} viruses following different vaccine regimens in ferrets. Ferrets (N=4/group) were inoculated with 10^7 PFU of VN04 H5N1 \textit{ca} intranasally or 200 \textmu g of vector or H5 HA DNA vaccine intramuscularly as indicated. Blood was collected 4 weeks after each dose and H5N1-specific antibody titers in the serum were determined by microneutralization (left panel) and HAI (right panel) assays. Geometric mean titers of neutralizing and HAI Ab against (A) VN04 (A/Vietnam/1203/2004), (B) HK03 (A/Hong Kong/213/2003), (C) AH05 (A/Anhui/1/2005), and (D) IN05 (A/Indonesia/5/2005) \textit{ca} viruses are depicted. Data points in black indicate titers of post-prime and data points in orange indicate titers of post-boost and the mean Ab titers are indicated in horizontal solid lines. The dashed line indicates the detection limit of the assays.

doi:10.1371/journal.pone.0021942.g003
virus boost induced immune response that could provide protection against homologous and heterologous H5N1 virus.

**Discussion**

The recent experience with the novel swine-origin 2009 H1N1 virus highlighted the importance of early, swift delivery and broad administration of vaccines during a pandemic. In the case of pH1N1 vaccine, a single dose without an adjuvant was highly immunogenic in adults and induced ~90% seroprotective conversion rate [30,31]. This is most likely due to the pre-existing cross-reactive antibodies to pH1N1 present in humans, especially the older adults who were previously exposed to seasonal H1N1 viruses [31,32]. However, many populations lack any pre-existing immunity against the novel H5N1 viruses that have sporadically infected humans. Thus, priming might be an important strategy to reduce the mortality and morbidity caused by the HPAI H5N1 viruses.

Unlike the 2009 H1N1 virus that has binding specificity for both α2,6-linked (human-like) and α2,3-linked (avian-like) sialic acid (SA) receptors [33,34], the H5N1 VN04 virus has binding preference for the α2,3-linked SA receptor [35]. The receptor binding preference of the H5N1 viruses may contribute to their inefficient transmission among humans and the low seroprevalence to this virus subtype among presumably exposed populations [36,37,38]. In addition, the glycosylation of the HA protein at position 158 also contributed to the low immunogenicity of VN04 virus [35]. Thus, priming susceptible populations with a pre-pandemic H5 vaccine would induce some cross-protective antibodies that could significantly augment the immunogenicity of an antigenically matched pandemic vaccine once it becomes available. The rapid immune response elicited by the pandemic vaccine, acting as a boosting agent, is expected to reduce the morbidity, mortality and transmission of the pandemic virus [33] and may decrease the number of doses required to achieve protective immunity.

In this study, the immunogenicity of the different vaccine regimens was assessed primarily by measuring HAI and Nt Ab in the serum of immunized ferrets. Although it is well established that LAIVs induce a robust mucosal immune response, we were unable to detect H5 HA-specific IgG and IgA antibody titers in the nasal wash due to assay insensitivity using the existing available ferret reagents in the ELISA assay. Two doses of iVN04 were not immunogenic in seronegative ferrets, consistent with the findings that purified protein antigens are not immunogenic in naïve animals [27]. However, priming with an adjuvanted iVN04 or VN04 virus could elicit high serum Nt Ab titers after the boost by either iVN04 or VN04 virus. These findings are in agreement with previous reports that adjuvants significantly improve the immunogenicity of inactivated H5N1 vaccines [39,40]. However, adjuvanted influenza vaccines are currently not licensed for use in the United States. Concerns over possible genetic reassortment with circulating influenza virus strains also restrict the use of an H5N1 LAIV for priming. Therefore, an alternative priming strategy is needed for future pandemics that are caused by novel subtypes. We found that a codon-optimized H5 HA DNA vaccine was comparable to an adjuvanted iVN04 as a priming agent. H5 HA DNA vaccination was not effective when administered alone by needle injection, inducing serum Nt or HAI Ab at levels below the detection limits. Our previous experience indicated that DNA immunization by intramuscular injection was not robust; thus, an additional DNA immunization was administered 2 weeks after the first dose in this study. This extra DNA dose did not appear to enhance DNA vaccine-mediated antibody response. However, the H5 HA DNA vaccine can prime the immune system to rapidly mount an immune response after boosting with VN04 virus vaccine, reaching serum Nt Ab titers comparable to that elicited by two doses of the live attenuated VN04 vaccine. The H5 HA DNA vaccine is an attractive alternative over an adjuvanted iVN04 because the DNA can be produced quickly, is relatively inexpensive to manufacture, and is amenable to long-term stockpiling.
H5N1 viruses continue to diversify and evolve in wild birds and domestic fowl [41]. It is highly desirable to produce a vaccine that is broadly cross-reactive to diverse strains. Ferrets that received 2 doses of VN04 α virus or the H5 HA DNA prime-VN04 α virus boost regimen had serum Nt and HAI Ab responses against antigenically distinct H5N1 viruses from different clades and prevented replication of a heterologous HK03 α virus vaccine. Our previous results indicate that mice immunized with a single dose of the VN04 α vaccine were protected from various lethal doses of heterologous H5N1 α viruses even in the absence of detectable Nt Ab in the serum, through a yet undefined immune mechanism [12]. Thus, the correlation between serum HAI or Nt Ab titers and protection from either lethal virus challenge or even virus replication in the respiratory tract of animals for H5N1 viruses is not firmly established. In this study, the ferrets that received the VN04 α vaccine (whether as a prime or as a boost) with detectable serum Nt and HAI Ab against antigenically diverse H5N1 viruses are expected to survive a lethal HPAI H5N1 virus challenge based on our previous report [12]. It was recently reported that priming with H1 HA DNA is associated with the induction of a broader Nt Ab response to temporally distant H1N1 strains and these Nt Ab target the conserved HA stem region [23]. Sera from ferrets that received either two doses of VN04 α virus or the H5 HA DNA prime-VN04 α virus boost regimen also recognized the HA2 region of a recombinant H5 HA and the H1 HA protein of a seasonal H1N1 virus, A/South Dakota/6/2007, by Western blotting (data not shown). We were not able to demonstrate clear broader reactivity against H5N1 subtypes of the animals primed with DNA followed by boost with the VN04 α virus. Even though H5 HA DNA vaccination elicited these HA2-binding antibodies, they were not sufficient to protect ferrets from replication of a heterologous H5N1 virus. Additional studies are required to determine the contributions of the stalk region-mediated response to subtypic and heterosubtypic immunity. It will also be important to understand the mechanism of protection induced by DNA vaccination and the contribution of cell-mediated immune responses to this protection.

Several strategies could be considered to further broaden the immune response elicited by H5 HA DNA priming by using heterologous H5 HA from genetically distinct clades or with multiple H5 HA DNA plasmids from representative H5N1 clades followed by boosting with the antigenically matched pandemic LAIV vaccine strain once it becomes available. A robust immune response towards the boosting strain can be achieved even when the doses are administered months or years apart [42,43,44]. A similar study is warranted to determine the durability of an H5 HA DNA priming so that the timing of additional doses could be planned. While the duration of protection conferred by the pandemic LAIV boost is not known, recent studies in children immunized with the seasonal trivalent LAIV show that relative efficacies against antigenically matched and mismatched strains can last more than 12 months post-vaccination [45,46]. Another option to improve the immunogenicity of H5 HA DNA priming is to adopt a more efficient gene delivery method such as the use of a gene gun or electroporation [47]. However, the accessibility, affordability, safety, and ease of operating such devices for DNA vaccine delivery may limit their use, especially in a pandemic setting [48]. In the current study, DNA priming with conventional needle injection was proven effective. However, we only evaluated H5N1 viruses in ferrets. The effectiveness of the DNA priming effect remains to be demonstrated for other influenza virus subtypes in pre-clinical studies; its safety and efficacy should be further evaluated in clinical studies.

**Materials and Methods**

**Generation of recombinant vaccine viruses**

Recombinant influenza VN04, HK03, IN05 and AH05 α viruses with multi-basic amino acids removed from the H5 HA cleavage site were generated as described previously [12]. Recombinant 6:2 viruses bearing the modified HA and unmodified NA from each H5N1 virus along with the six internal protein gene segments of AA α were rescued using the eight-plasmid transfection system [11,49]. Viruses were amplified in the allantoic cavity of 10–11 day old embryonated chicken eggs. Viral titer was determined by plaque assay or 50% tissue culture infectious dose (TCID50) in Madin-Darby canine kidney (MDCK) cells.

**Codon-optimized H5 HA DNA vaccines**

The codon optimized H5-VN.tPA DNA expressing the full length HA0 was cloned into DNA vaccine vector pSW3891 under a human tissue plasminogen activator (tPA) leader sequence. The DNA vaccine plasmid was prepared from *Escherichia coli* (HB101 strain) with a Mega purification kit (Qiagen, Valencia, CA) for both in vitro transfection and in vivo animal immunization studies. The HA protein expression was examined by transient transfection of 293T cells and Western blot analysis as previously described [28].

**Ferret studies**

Eight- to ten-week old ferrets from Simonsen (Gilroy, CA) that were seronegative for antibodies to seasonal H1N1, H3N2 and H5N1 α viruses were used in the studies. All animals were anesthetized with isoflurane prior to immunization. In the first experiment, 8 groups of 4 ferrets were primed with bilateral intra-muscular (i.m.) injections of one of the following: (1) PBS; (2) 15 μg of iVN04 (NR-4143, Bio defense and Emerging Infections Research Resources Repository, NIAID, NIH, Bethesda, MD); (3) 15 μg of iVN04 with the adjuvant TiterMax (TiterMax, USA); or (4) intra-nasally (i.n.) with 10^7 PFU of VN04 α virus. Four weeks after the first dose, ferrets were immunized with PBS, iVN04 or VN04 α virus. H5 HA-specific antibody responses were evaluated using sera collected on days 28 and 56 post-vaccination.

In the second experiment, 5 groups of 4 ferrets were vaccinated with bilateral i.m. injections of one of the following: (1) 200 μg of plasmid vector (Group 1); (2) i.n. inoculation of 10^7 PFU of VN04 α virus (Groups 2–3) or (3) codon-optimized H5 HA DNA plasmid (Groups 4–5). Two weeks after priming, a group of ferrets that were primed with the H5 HA DNA vaccine received a second dose of the H5 HA DNA vaccine. Four weeks after the first dose, ferrets were immunized with PBS, H5 HA DNA or VN04 α virus. Four weeks after the boost, all ferrets were i.n.-infected with 10^7 PFU of HK03 α virus. Ferrets were sacrificed on day 3 post-infection, the nasal turbinates were harvested and virus titers in the upper respiratory tract of ferrets was determined by 50% egg infectious dose (EID<sub>50</sub>) assay and expressed as log<sub>10</sub> EID<sub>50</sub>/g of tissue. H5 HA-specific antibody responses were evaluated using sera collected on days 14, 28, 42 and 56 post-vaccination. All animal studies were conducted in accordance with the Institutional Animal Care and Use Committee-approved protocols (058-07-035 and 081-09-053).

**HAI and microneutralization assays**

Influenza-specific serum antibody responses against the homologous and heterologous H5N1 viruses of immunized ferrets were determined by microneutralization assay and HAI assay. Briefly, serum samples were treated with receptor-destroying enzyme (Denka-Seiken, Tokyo, Japan) at 37°C overnight followed by heat-
inactivation at 56°C for 45 min. For HAI assay, serial 2-fold dilutions of serum were incubated with an equal volume of 4 HA units of the indicated H5N1 virus in a 96-well V-bottom plate for 1 hr, followed by the addition of either 1.0% horse erythrocytes (Lampire Biological Laboratories, Pipersville, PA) containing 0.5% BSA (against VN04, AN05 and EN05) or 0.5% turkey erythrocytes (Lampire Biological Laboratories, Pipersville, PA) (against HK03). HAI antibody titers were defined as the reciprocal of the highest serum dilution that completely inhibited hemagglutination. For microneutralization assays, serial 2-fold dilutions of serum were incubated with an equal volume of 100 TCID50 of the indicated H5N1 virus at 33°C for 1 hr. The virus-serum mixture was then transferred to monolayers of MDCK cells and incubated at 33°C for 6 days. Neutralizing antibody titer was defined as the reciprocal of the highest dilution of serum that completely neutralized virus infectivity as indicated by the absence of cytopathic effects (CPE) on day 6 post-infection.

ELISA
An enzyme-linked immunosorbent assay (ELISA) was conducted to measure H5 HA-specific IgG and IgA antibody titers in the sera of immunized ferrets. Half of a 96-well flat bottom plate (Costar, Corning, NY) were coated with 0.05 μg of recombinant VN04 H5 HA protein (Protein Sciences, Meriden, CT) and the other half of the plates were incubated with 100 μl of PBS. The plates were incubated at 4°C overnight, washed 3x with PBS containing 0.05% Tween 20 (Sigma, St. Louis, MO), and then blocked with 300 μl of blocking buffer (SuperBlock blocking buffer; Thermoscientific, Rockford, IL) for 1 hr at 37°C. After removing the blocking buffer from the plates, serial 4-fold dilutions of serum samples (in 10% SuperBlock blocking buffer + 0.05% Tween 20) for IgG assay or serial 2-fold dilutions of serum samples (for IgA assay) were added to the wells with or without the coating antigen, and incubated for 1 hr at 37°C. After washing, the plates were incubated with 100 μl of 1:10,000 dilution in 10% SuperBlock + 0.05% Tween 20) of goat-anti-ferret IgG conjugated to horse radish peroxidase (Bethyl Laboratories, Inc., Montgomery, TX) (for IgG assay) or 100 μl of 1:2,500 dilution of goat anti-ferret IgA (Bethyl Laboratories, Inc., Montgomery, TX) conjugated to biotin (EZ-link Sulfo-NHS-SS-biotinylation kit, ThermoScientific, Rockford, IL) for IgA assay) for 45 min at 37°C. After washing, the IgA plates were further incubated with 1:10,000 dilution of streptavidin-HRP (ThermoScientific, Rockford, IL) for 30 min at 37°C. Both IgG and IgA assay plates were developed with 100 μl of 3,3’,5,5’-tetramethylbenzidine (TMB) substrate solution (Sigma, St. Louis, MO); IgG plates were incubated for 5 min at room temperature while IgA plates were incubated for 30 min at 37°C. The reactions were stopped by adding 100 μl of 1 N H2SO4 and the absorbance were read at A = 450 nm. The difference in the OD readings of each diluted sample between wells coated with or without the H5 HA antigen was determined, and the H5 HA-specific IgG and IgA titers were defined as the reciprocal of the highest dilution that gave a AOD value ≥ 0.200.

Acknowledgments
We thank the Biodefense and Emerging Infections Research Resources Repository (NIAID, NIH, Bethesda, MD) for supplying inactivated H5N1 influenza vaccine. The live attenuated H5N1 candidate vaccines were produced under the Cooperative Research and Development Agreement (CRADA) between MedImmune and NIAID/NIH. We thank MedImmune’s Animal Care Facility for conducting the ferret experiments, Dr. Gary Van Nest for reviewing the manuscript, and members of HJ’s group for discussions.

Author Contributions
Conceived and designed the experiments: HJ ALS XC SL. Performed the experiments: ALS XC WW SW. Analyzed the data: ALS XC HJ. Contributed reagents/materials/analysis tools: SW XL. Wrote the paper: ALS HJ SW SL.

References
1. Johnson NP, Mueller J (2002) Updating the accounts: global mortality of the 1918-1920 “Spanish” influenza pandemic. Bull Hist Med 76: 105–113.
2. Glezen WP (1996) Emerging infections: pandemic influenza. Epidemiol Rev 18: 64–76.
3. WHO (2010) Cumulative Number of Confirmed Human Cases of Avian Influenza A/H5N1 Reported to WHO.
4. Chen H SG, Li KS, Wang J, Fan XH, Rayner JM, et al. (2006) Establishment of multiple sublines of H5N1 influenza virus in Asia: implications for pandemic control. Proc Natl Acad Sci USA 103: 2845–2850.
5. Otsavins GA, Ozawa M, Yamada S, Goto H, Kawaoka Y (2010) High level of genetic compatibility between swine-origin H1N1 and highly pathogenic avian H5N1 influenza viruses. J Virol 84: 10918–10922.
6. Maassab HF (1969) Biologic and immunologic characteristics of cold-adapted influenza virus. J Immunol 102: 729–732.
7. Clements ML, Betts RF, Tierney EL, Murphy BR (1986) Serum and nasal wash antibodies associated with resistance to experimental challenge with influenza A virus in wild-type and CD8 T cell-depleted mice. J Immunol 137: 1918–1922.
8. Maas HF (1969) Biologic and immunologic characteristics of cold-adapted influenza virus. J Immunol 102: 729–732.
9. Powers DC, Murphy BR, Thamar E, Clements ML (1989) Systemic and local antibody responses in elderly subjects given live or inactivated influenza A virus vaccines. J Clin Microbiol 27: 2666–2671.
10. Gorse GJ CM, Otto EE, Powers DC, Chambers GW, Newman FK (1993) Increased anti-influenza A virus cytotoxic T cell activity following vaccination of the chronically ill elderly with live attenuated or inactivated influenza A virus vaccine: importance of interferon-gamma production and local IgA response. Vaccine 11: 187–190.
11. Jin H, Lu B, Zhou H, Ma C, Zhao J, et al. (2003) Multiple amino acid residues confer temperature sensitivity to human influenza virus strain (FluMist) derived from cold-adapted A/H1N1/70. Virology 306: 18–24.
12. Sugatani AL, Jr., McAuliffe J, Mills KL, Jin H, Duke G, et al. (2006) Live-attenuated influenza A H5N1 candidate vaccines provide broad cross-protection in mice and ferrets. PLoS Med 3: e260.
13. Ulmer JB, Fu TM, Deck RR, Friedman A, Guan L, et al. (1998) Protective CD4+ and CD8+ T cells against influenza virus induced by vaccination with nucleoprotein DNA. J Virol 72: 5648–5653.
14. Epstein SL, Tumpey TM, Milpilon JA, Lo CY, Cooper LA, et al. (2002) DNA vaccine expressing conserved influenza virus protein protective against H5N1 infection in mice. Emerg Infect Dis 8: 796–801.
15. Lalor PA, Webby RJ, Morrow J, Rusakov D, Kaslow DG, et al. (2008) Plasmid DNA-based vaccines protect mice and ferrets against lethal challenge with A/Vietnam/1203/04 (H5N1) influenza virus. J Infect Dis 197: 1643–1652.
16. Wang S, Parker C, Taaffe J, Solorzano A, Garcia-Sastre A, et al. (2008) Heterologous HA DNA vaccine prime—inactivated influenza vaccine boost is more effective than using DNA or inactivated vaccine alone in eliciting antibody responses against H1 or H5 subtype influenza viruses. Vaccine 26: 3626–3633.
17. Tanghe A, D’Souza S, Rosseels V, Denis O, Ottenhoff TH, et al. (2001) Improved immunogenicity and protective efficacy of a tuberculosis DNA vaccine encoding Ag85 by protein boosting. Infect Immun 69: 3014–3017.
18. Kongkasuriyachai D, Bartels-Andrews L, Stowers A, Collins WE, Sullivan J, et al. (2008) Potent immunogenicity of DNA vaccines encoding Plasmodium vivax transmission-blocking vaccine candidates Pvs25 and Pvs28—evaluation of homologous and heterologous antigen-delivery prime-boost strategy. Vaccine 22: 3205–3213.
19. Xu G, Wang S, Zhuang L, Hackett A, Gu L, et al. (2009) Intramuscular delivery of a cholera DNA vaccine primes both systemic and mucosal protective antibody responses against cholera. Vaccine 27: 3821–3830.
20. Li YH, Huang S, Du M, Biao Z, Chen Z, et al. (2010) Immunogenic characterization and protection against Streptococcus mutans infection induced by intranasal DNA prime-protein boost immunization. Vaccine 28: 5370–5376.
21. Zhou Y, Lu F, Dai Y, Wang X, Tang J, et al. (2010) Synergistic enhancement of immunogenicity and protection in mice against Schistosoma japonicum with codon optimization and electroporation delivery of SJTTI DNA vaccines. Vaccine 28: 5347–5353.
22. Wang S, Kennedy JS, West K, Montefiori DC, Coley S, et al. (2008) Cross-subtype antibody and cellular immune responses induced by a polyvalent DNA-prime-protein boost HIV-1 vaccine in healthy human volunteers. Vaccine 26: 3947–3957.
23. Wei CJ, Boyington JC, McManney PM, Kong WP, Pearce MB, et al. (2010) Induction of broadly neutralizing H1N1 influenza antibodies by vaccination. Science 329: 1060–1064.

24. Huber VC, Thomas PG, McCallers JA (2009) A multi-valent vaccine approach that elicits broad immunity within an influenza subtype. Vaccine 27: 1192–1200.

25. Trenor JJ, Campbell JD, Zaugwoll KM, Rowe T, Wolff M (2006) Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N Engl J Med 354: 1545–1551.

26. Zaugwoll KM, Trenor JJ, Campbell JD, Noah DL, Rya J (2008) Evaluation of the safety and immunogenicity of a booster (third) dose of inactivated subvirion H3N1 influenza vaccine in humans. J Infect Dis 197: 580–583.

27. Koyama K, Aoshi T, Tanimoto T, KumaIgai Y, Kobiyama K, et al. (2010) Plasmacytoid dendritic cells delineate immunogenicity of influenza vaccine subtypes. Sci Transl Med 2: 23ea24.

28. Wang S, Taafel F, Parker C, Solorzano A, Cao H, et al. (2006) Hemmagglutinin (HA) proteins from H1 and H3 serotypes of influenza A viruses require different antigen designs for the induction of optimal protective antibody responses as studied by codon-optimized HA DNA vaccines. J Virol 80: 11628–11637.

29. Hauser S, Madihan A, Cox RJ, Haaheim LR (2007) Quality and kinetics of the antibody response in mice after three different low-dose influenza virus vaccination strategies. Clin Vaccine Immunol 14: 976–983.

30. Greenberg ME, Lai MH, Hartel GF, Wichems CH, Gittleson C, et al. (2010) A single dose of unadjuvanted novel 2009 H1N1 vaccine is immunogenic and well tolerated in young and elderly adults. J Infect Dis 202: 1327–1337.

31. Nolan T, McVernon J, Skeljo M, Richmond P, Wadia U, et al. (2010) Immunogenicity of a monovalent 2009 influenza A (H1N1) vaccine. N Engl J Med 361: 2405–2413.

32. Talata KR, Greenberg ME, Lai MH, Hartel GF, Wichems CH, et al. (2010) A single dose of unadjuvanted novel 2009 H1N1 vaccine is immunogenic and well tolerated in young and elderly adults. J Infect Dis 202: 1327–1337.

33. Nolan T, McVernon J, Skeljo M, Richmond P, Wadia U, et al. (2010) Immunogenicity of a monovalent 2009 influenza A(H1N1) vaccine in infants and children: a randomized trial. JAMA 303: 37–46.

34. Jennings LC, Monto AS, Chan PK, Szucs TD, Nicholson KG (2008) Stockpiling prepandemic influenza vaccines: a new cornerstone of pandemic preparedness plans. Lancet Infect Dis 8: 650–658.

35. Chen Z, Wang W, Zhou H, Suguitan AL, Jr., Shambaugh C, et al. (2010) Generation of live attenuated novel influenza virus A/California/7/09 (H1N1) vaccines with high yield in embryonated chicken eggs. J Virol 84: 44–51.

36. Wang W, Lu B, Zhou H, Suguitan AL, Jr., Cheng X, et al. (2010) Glycosylation at 158N of the hemagglutinin protein and receptor binding specificity synergistically affect the antigenicity and immunogenicity of a live attenuated H5N1 A/Vietnam/1203/2004 vaccine virus in ferrets. J Virol 84: 6570–6577.

37. Depichi R, Laesrimtaworn Y, Phuthavathana P, Uyeki TM, O'Reilly M, et al. (2009) Seroprevalence of antibodies to avian influenza virus A (H5N1) among residents of villages with human cases, Thailand, 2005. Emerg Infect Dis 15: 756–760.

38. Santhia K, Ramy A, Jayaningsih P, Samaan G, Putra AA, et al. (2009) Avian influenza A H5N1 infections in Bali Province, Indonesia: a behavioral, virological and seroepidemiological study. Influenza Other Respi Viruses 3: 81–89.

39. Nicholson KG, Colegate AE, Dodd A, Stephenson I, Wood J, et al. (2001) Safety and immunogenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza. Lancet 357: 1937–1943.

40. Leroux-Roels I, Berkowski A, Vanwolleghem T, Drame M, Clement F, et al. (2007) Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. Lancet 367: 580–589.

41. Li Y, Shi J, Zhong G, Deng G, Tian G, et al. (2010) Continued evolution of H5N1 influenza viruses in wild birds, domestic poultry, and humans in China from 2004 to 2009. J Virol 84: 3839–3839.